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Zhang et al. report on the role of the ATP-
conducting mitochondrial outer
membrane voltage-dependent anion
channel-1 (VDAC1) in b cell glucotoxicity
preceding diabetes. VDAC1 upregulation
leads to ATP depletion and impaired
insulin secretion. VDAC1 inhibitors,
including metformin, restore insulin
secretion in T2D islet donors and prevent
hyperglycemia in diabetic mice.
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Type 2 diabetes (T2D) develops after years of predia-
betes during which high glucose (glucotoxicity)
impairs insulin secretion. We report that the ATP-
conducting mitochondrial outer membrane voltage-
dependent anion channel-1 (VDAC1) is upregulated
in islets from T2D and non-diabetic organ donors un-
der glucotoxic conditions. This is caused by a gluco-
toxicity-induced transcriptional program, triggered
during years of prediabetes with suboptimal blood
glucose control. Metformin counteracts VDAC1
induction. VDAC1 overexpression causes its mistar-
geting to the plasma membrane of the insulin-
secreting b cells with loss of the crucial metabolic
coupling factor ATP. VDAC1 antibodies and inhibi-
tors prevent ATP loss. Through direct inhibition
of VDAC1 conductance, metformin, like specific
VDAC1 inhibitors and antibodies, restores the
impaired generation of ATP and glucose-stimulated
insulin secretion in T2D islets. Treatment of db/db
mice with VDAC1 inhibitor prevents hyperglycemia,
and maintains normal glucose tolerance and physio-
logical regulation of insulin secretion. Thus, b cell
function is preserved by targeting the novel diabetes
executer protein VDAC1.
INTRODUCTION
Type 2 diabetes (T2D) is steadily increasing and represents a
worldwide health problem. The majority of cases occur second-
ary to obesity with its associated insulin resistance. T2D de-
velops after years of prediabetes, or impaired glucose tolerance
(IGT). The disease becomes manifest when insulin resistance is
no longer compensated by augmented insulin secretion (Aroda64 Cell Metabolism 29, 64–77, January 8, 2019 ª 2018 The Authors.
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Accordingly, monitoring the insulin secretory capacity of pancre-
atic b cells best predicts future diabetes (Lyssenko et al., 2008).
During prediabetes, blood glucose values gradually increase,
exerting harmful effects on a wide variety of organs, including
the cardiovascular system and the b cells in the pancreatic islets,
so-called glucotoxicity (Wajchenberg, 2007; Weir and Bonner-
Weir, 2004). Lifestyle modifications can prevent the outbreak
of T2D and revert early stages of the disease but are difficult
to implement. No current medication can efficiently preserve
b cell function or prevent T2D (Aroda et al., 2017). Among the
commonly used T2D drugs, metformin acts mainly, but not
exclusively, by suppressing glucose production in the liver (re-
viewed in Foretz et al., 2014), while thiazolidinediones enhance
peripheral insulin sensitivity and sulfonylureas force the secre-
tion of more insulin from the already stressed b cells (Wajchen-
berg, 2007). Additional antidiabetic drugs have been introduced.
Among these, glucagon-like peptide-1 (GLP-1) analogs and
dipeptidyl peptidase-4 inhibitors enhance insulin secretion,
while sodium-glucose cotransporter-2 inhibitors lower blood
glucose by preventing renal glucose reabsorption (Palanisamy
et al., 2018).
Dysfunction of the b cells with impaired glucose-stimulated in-
sulin secretion (GSIS) is the main defect in T2D, since the reduc-
tion in b cell mass varies greatly between different studies (for re-
view, see Marselli et al., 2014; Meier and Bonadonna, 2013). The
b cell is particularly sensitive to caloric overload, as GSIS is
attenuated after glucose infusion in healthy subjects (Boden
et al., 1996) and after culture of human islets under glucotoxic
conditions (Masini et al., 2014). Genetic factors predispose for
b cell decompensation, and more than 100 T2D risk genes
have been described, most of which encode b cell proteins
(Fadista et al., 2014). Nonetheless, even combined, these risk al-
leles only explain the disease predisposition in 10%–15% of
cases. Therefore, attention has focused on epigenetic changes
conferred by high caloric intake and other diabetes risk factors
(Nilsson and Ling, 2017). In particular, the stress-induced gene
thioredoxin-interacting protein (TXNIP) is upregulated in isletsPublished by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. Expression of VDAC1 and VDAC2 in
Human Pancreatic Islets
(A) VDAC1 and VDAC2 mRNA levels in islets from
non-diabetic (ND) and T2D donors. Mean ± SEM of
19 ND and 18 T2D.
(B) Positive correlation between islet VDAC1 mRNA
and donor HbA1c in ND (HbA1c < 6.0%) (n = 15; R2 =
0.83, p < 0.005); insert, correlation for ND + T2D,
n = 30 including the four metformin-treated (red
dots), R2 = 0.27; p < 0.05.
(C) VDAC1 expression in islets from ND (n = 15), all
T2D (n = 15), and four of these T2Dwith documented
metformin therapy.
(D) Negative correlation between islet VDAC2mRNA
and donor HbA1c in ND (n = 14; R2 = 0.28; p < 0.05).
Correlation for ND + T2D: n = 30 including the four
metformin-treated (red dots), R2 = 0.39; p < 0.05
(insert).
(E) VDAC2 expression in islets from ND (n = 14), all
T2D (n = 15), and four of these T2Dwith documented
metformin therapy.
(F and G) Glucotoxic condition (20 mM culture, 24
and 72 hr) mimics the T2D profile of VDAC1
expression in human islets. Metformin (20 mM) pre-
vents the VDAC1 induction at 72 hr (F) and VDAC2
suppression (G) (n = 3–5 donors).of T2D organ donors and in b cells exposed to glucotoxic condi-
tions (Bompada et al., 2016; Shalev, 2014). Its deletion prevents
diabetes in rodents (Shalev, 2014). Glucose induces TXNIP
expression by increasing the epigenetic histone acetylation of
the TXNIP gene (Bompada et al., 2016; Cha-Molstad et al.,
2009). However, the mechanism underlying the harmful effects
of TXNIP induction in the b cell remains to be clarified.
ATP generated by glucose oxidation in b cell mitochondria
couples metabolism to plasma membrane depolarization, which
increases cytosolic Ca2+ and insulin exocytosis (Wiederkehr and
Wollheim, 2012). This signaling cascade is impaired in T2D,
mainly due to defective mitochondrial metabolism (Anello
et al., 2005; Doliba et al., 2012; MacDonald et al., 2009). The
voltage-dependent anion channel (VDAC) is the most abundant
protein of the outer mitochondrial membrane. VDAC1 and
VDAC2 determine cell life and death by regulating flux of metab-
olites, nucleotides, including ADP and ATP, as well as ions
between the mitochondria and the cytosol, while the VDAC3 iso-
form is less well characterized (Naghdi and Hajnoczky, 2016;
Shoshan-Barmatz et al., 2010). There is a striking comorbidity
between T2D andAlzheimer’s disease (AD) (Ribe and Lovestone,
2016). In AD, VDAC1 is induced early in the disease, associated
with its overexpression in the neurolemma (Fernandez-Echevar-
ria et al., 2014). Moreover, VDAC1 antibodies protect cells fromCeamyloid b (Ab) peptide-induced neurotox-
icity (Akanda et al., 2008; Smilansky et al.,
2015). Such effects have not been reported
in T2D. Therefore, we investigated the
involvement of VDAC in b cell glucotoxicity.
In particular, we studied the transcriptional
program induced by glucose in insulinoma
cells and human pancreatic islets. The role
of VDAC1 in the development of hypergly-cemia was also examined in the db/db mouse, a commonly
used diabetes model. We report that VDAC1 overexpression
and mistargeting to the b cell plasma membrane in T2D causes
ATP loss. Direct inhibition of VDAC1 in human T2D b cells re-
stores GSIS and prevents development of diabetes in db/db
mice. Metformin also acutely improves GSIS by directly blocking
VDAC1 channel function, a hitherto not appreciated mode of
action of the antidiabetic drug.
RESULTS AND DISCUSSION
Altered VDAC Expression in T2D Islets and after
Glucotoxicity
Islets from T2D organ donors (Table S1 for donor characteristics)
display upregulated VDAC1 mRNA, while VDAC2 mRNA is
repressed, compared with islets from non-diabetic (ND) donors
(Figure 1A). These results were substantiated at the protein level
(Figures S1A and S1B). VDAC1 mRNA is strikingly correlated
with average blood glucose during the months preceding the
demise (glycated A1c, HbA1c) in ND islets (Figure 1B). When
the results obtained in T2D donors are included, the correlation,
albeit significant, is less marked (Figure 1B, insert).
Metformin is the most frequently used antidiabetic medication
(Foretz et al., 2014). We could document four donors withll Metabolism 29, 64–77, January 8, 2019 65
metformin therapy. The correlation between HbA1c and VDAC1
expression wasmore significant when themetformin-treated do-
nors were excluded (Figure S1C). Accordingly, the islets from the
metformin-treated donors did not display increased VDAC1
mRNA (Figure 1C). Conversely, there was a negative correlation
between HbA1c and islet VDAC2 mRNA (Figure 1D), which was
only marginally changed by removal of the metformin-treated
donors (Figures 1D insert, S1D, and 1E for islet mRNA levels).
We identified two abundantly expressed VDAC1 transcript vari-
ants (Figures S1E–S1G). Of note, one of these VDAC1 transcript
variants appears to be induced by hyperglycemia, as the
elevated expression in T2D donors is already seen in part in islets
from IGT donors (Figure S1G). This suggests that impaired blood
glucose control drives VDAC1 overexpression, while VDAC2
downregulation, albeit significant, is less pronounced. To eval-
uate if the changes observed in T2D islets can be linked to glu-
cotoxicity, we cultured human islets under glucotoxic conditions
(20 mM glucose for 72 hr), known to attenuate GSIS in human is-
lets (Masini et al., 2014). Exposure to high glucose reproduces
the T2D profile, increasing VDAC1 and decreasing VDAC2
mRNA (Figures 1F and 1G). However, culture of the islets at
10 mM glucose does not induce VDAC1, whereas VDAC2
mRNA is suppressed (Figure S1F). It may be speculated that
increased VDAC1 requires longer time culture at high physiolog-
ical glucose concentrations; while VDAC2 suppression is more
sensitive to elevated glucose. The changes in VDAC1 and
VDAC2 under glucotoxic conditions were substantiated at the
protein level for both human islets and rat insulinoma INS-1 cells
(Figure S1I). To study the effect of metformin, we cultured ND hu-
man islets under glucotoxic conditions in the presence of 20 mM
metformin, corresponding to plasma concentrations during drug
treatment (Foretz et al., 2014). As shown in Figures 1F and 1G,
the inclusion of metformin in the culture medium prevents the
alterations in VDAC1 and VDAC2 mRNA levels. These results
confirm the observations in metformin-treated islet donors.
Altered VDAC Expression Does Not per se Cause
Apoptosis
In most investigated tissues and cells, VDAC1 is much
more abundant than VDAC2 (Naghdi and Hajnoczky, 2016;
Shoshan-Barmatz et al., 2010), while VDAC2 mRNA is higher
than VDAC1mRNA in human b cells (Blodgett et al., 2015).More-
over, VDAC2 protein ismore abundant than VDAC1 in INS-1 cells
(Figure S1J). This may suggest an important role for VDAC2 in
b cells. It is noteworthy that manipulations of VDAC1 and
VDAC2 expression in b cells led to reciprocal changes, overex-
pression of VDAC1 suppresses VDAC2, and silencing of
VDAC2 increases VDAC1 (Figures S2A and S2B for INS-1 cells;
Figures S2G and S2H for human islets). Therefore, altered
expression of either isoform could impact on b cell function.
Metabolic and oxidative stress are known to upregulate
VDAC1 and cause its oligomerization with ensuing apoptosis
(Shoshan-Barmatz et al., 2017). To address this question, we
measured apoptosis in INS-1 cells after overexpression of
Vdac1 or knockdown of Vdac2, reaching changes in VDAC pro-
tein levels similar to those of T2D islets and islets or INS-1 cells
cultured under glucotoxic conditions (cf. Figure S1G). Evaluation
of cell death by determining cytoplasmic nucleosomes in INS-1
cells after overexpression of Vdac1 or Vdac2 downregulation66 Cell Metabolism 29, 64–77, January 8, 2019at 5 mM glucose shows no significant increase in apoptosis. In
contrast, altered VDAC1 expression combined with 20 mM
glucose culture, results in marked cell death (Figure S2C).
Thus, the diabetes-associated alteration in VDAC expression
profile does not per se cause b cell death, suggesting that addi-
tional insults trigger apoptosis. In this context, it should be
emphasized that while loss of functional b cell mass in T2D is
well documented, the contribution of b cell death is debated
(Marselli et al., 2014; reviewed in Meier and Bonadonna, 2013).
Therefore, we focused on the role of the two VDAC isoforms in
b cell function.
Changes in VDAC Expression Impair Mitochondrial
Function
We first examined insulin secretion in INS-1 cells. GSIS is mark-
edly inhibited after Vdac1 overexpression or Vdac2 knockdown
(Figures 2A and 2B). In T2D islets, mitochondrial dysfunction un-
derlies the blunted GSIS (Anello et al., 2005; Doliba et al., 2012).
We therefore assessed mitochondrial oxygen consumption rate
(OCR). OCR is inhibited both at non-stimulatory (2.8 mM) and
stimulatory (16.7 mM) glucose concentrations in cells with
altered Vdac isoform expression (Figures 2C and 2D; see S2A
and S2B for expression levels). The same phenotype with
reduced OCR is reproduced by cell culture under glucotoxic
conditions (Figures 2E and 2F), further implicating altered
VDAC function in the b cell defect.
Glucose oxidation in the b cell mitochondria increases the
crucial intracellular signaling molecules ATP and Ca2+, which
couplemetabolism to insulin exocytosis (Doliba et al., 2012;Wie-
derkehr et al., 2011; Wiederkehr andWollheim, 2012). Therefore,
we next monitored glucose-induced increases in cytosolic and
mitochondrial Ca2+ during acute stimulation. As expected from
the attenuated GSIS, the increases in both cytosolic and mito-
chondrial Ca2+ evoked by glucose are markedly blunted in cells
with upregulated VDAC1 or downregulated VDAC2, aswell as af-
ter glucotoxic treatment (Figures S2D–S2F). Thus, these results
strongly support the involvement of altered VDAC expression
in the impairedmetabolism-secretion coupling evoked by gluco-
toxicity. VDAC1 is essential in the function of endoplasmic retic-
ulum-mitochondria contact sites (De Pinto et al., 2010; Shoshan-
Barmatz et al., 2017). Decreased VDAC1 protein in these contact
sites was observed in human T2D b cells (Thivolet et al., 2017).
Thus, not only altered VDAC gene expression but also protein
localization could contribute to the mitochondrial dysfunction.
Changes in VDAC Expression Explain Blunted GSIS in
Human Islets
Subsequently, we investigated whether human islets can be pro-
tected from glucotoxicity by silencing VDAC1. Knockdown of
VDAC1 results in upregulation of VDAC2 mRNA, while VDAC2
silencing increases VDAC1 expression as in INS-1 cells (Figures
S2G and S2H). Remarkably, VDAC1 knockdown not only pre-
vents the suppression of VDAC2 induced by culture in 20 mM
glucose, but VDAC2 mRNA is considerably higher than in islets
maintained at 5 mM glucose (Figures S2G and S2H). To evaluate
the impact of altered VDAC expression, we first measured over-
all cellular reductive capacity, which is conveniently monitored
by formazone production from tetrazolium, reflecting b cell mito-
chondrial metabolism (Janjic and Wollheim, 1992). Reductive
Figure 2. Impact of VDAC1 on b Cell Function
(A and B) Glucose-stimulated insulin secretion (GSIS) in INS-1 cells after overexpression of Vdac1 (OE) (A) or knockdown (KD) of Vdac2 (B) (n = 5).
(C) Oxygen consumption rate (OCR) in INS-1 cells after overexpression of Vdac1 or KD of Vdac2. Subsequent additions were as follows: oligomycin ([Olig], an
inhibitor of ATP synthase) (0.4 mM), dinitrophenol ([DNP], an uncoupler) (0.4 mM), and rotenone ([Rot], an inhibitor of complex (I) (0.1 mM).
(D) Area under the curve (AUC) for the experiments in (C) (n = 5).
(E and F) OCR of INS-1 cells cultured at 5 or 20 mM glucose (72 hr) (n = 5).
(G) VDAC1 silencing protects human islet cells from glucotoxicity-induced decrease in cellular reductive capacity (formazone production), while VDAC2 KD is
harmful. Islets from five donors (used in separate experiments) were cultured at either 5 or 20 mM glucose for 72 hr.
(H) Effect of VDAC1 or VDAC2 KD on ATP content of islets cultured at 5 or 20 mM glucose (72 hr) and incubated at 1 or 16.7 mM glucose for 1 hr (n = 3 donors).
(I) Insulin secretion for the same islets as in (H).capacity in 5mMglucose-cultured islets is not altered by VDAC1
knockdown, which, however, completely prevents the marked
impairment under the glucotoxic condition. In contrast, VDAC2
silencing evokes similar low overall cellular reductive capacity
as 20mMglucose culture (Figure 2G). These results are substan-tiated by measurements of ATP content and insulin secretion
after 1 hr incubation of islets after prior culture at either 5 or
20 mM glucose. In the glucotoxic islets, 16.7 mM glucose-
induced increases in ATP and insulin secretion are abrogated.
Like reductive capacity, silencing of VDAC1 preserves basalCell Metabolism 29, 64–77, January 8, 2019 67
Figure 3. Transcriptional Program Causing VDAC1 Overexpression after Glucotoxicity
(A) ChREBP and TXNIP mRNA is increased in T2D islets (n = 4–5 donors).
(B) Vdac1 overexpression is blunted after silencing of either Chrebp or Txnip in 20 mM glucose-cultured INS-1 cells (n = 5).
(C) Glucose-evoked ChREBP induction is prevented in histone acetyltransferase p300 knockout INS-1 (Ep300/) cells.
(D) Txnip expression is suppressed in INS-1 (Ep300/) cells after 5 mM glucose culture. Txnip induction is blunted at 20 mM glucose.
(E) VDAC1 is not induced by glucotoxicity in INS-1 (Ep300/) cells.
(F) VDAC2 is upregulated in INS-1 (Ep300/) cells at 5 mM and further increased after culture at 20 mM glucose (n = 3–4).
(G) INS-1 (Ep300/) cells are partially protected from blunting of GSIS after culture at 20 mM glucose (n = 3–4). Independent experiments given as n.ATP levels and rescues glucose-evoked increases in ATP and in-
sulin secretion. In contrast, VDAC2 suppression reduces basal
islet ATP and blunts both ATP elevation and stimulated insulin
secretion (Figures 2H and 2I). Taken together, the altered
VDAC expression profile in glucotoxic cells impairs mitochon-
drial metabolism and, as a consequence, GSIS, while the impact
on b cell viability is less pronounced.
VDAC1 Induction by Epigenetic Activation of TXNIP
Next, we investigated the transcriptional program induced by
glucotoxicity. It is well documented that glucotoxicity in the
b cell, like oxidative stress, upregulates TXNIP by the induction
and nuclear transfer of the carbohydrate response element-
binding protein (ChREBP) (Poungvarin et al., 2012; Shaked
et al., 2011; Shalev, 2014). This genetic program is also activated
by the non-metabolizable glucose analog 2-deoxyglucose,
which promotes metabolism-independent nuclear transfer of
ChREBP (Shaked et al., 2011; Shalev, 2014). T2D islets display
increased transcripts of both ChREBP and TXNIP (Figure 3A),
confirming published results (Bompada et al., 2016; Poungvarin
et al., 2012; Shalev, 2014). Vdac1 induction by 2-deoxyglucose
in INS-1 cells (Figure S3A) substantiates the involvement of
ChREBP and TXNIP in VDAC1 gene regulation by glucotoxicity.
Moreover, knockdown of either Chrebp or Txnip in INS-1 cells68 Cell Metabolism 29, 64–77, January 8, 2019prevents glucotoxicity-induced Vdac1 upregulation (Figure 3B;
for silencing efficacy, see Figures S3B and S3C). The transcrip-
tional activation of TXNIP by glucose requires not only ChREBP
dimerization with MLX, but also the recruitment of the histone
acetyltransferase p300 (Ep300) for efficient transcription (Bom-
pada et al., 2016; Cha-Molstad et al., 2009). Ep300 activity is
necessary for glucose-induced TXNIP upregulation in human is-
lets and INS-1 cells by altering histone acetylation marks in the
TIXNIP gene (Bompada et al., 2016). To further characterize
the roles of ChREBP and TXNIP in VDAC expression, we used
INS-1 cells with Ep300 knockout (KO) established by CRISPR/
Cas9 (Bompada et al., 2016). As expected, INS-1 (Ep300/)
cells exhibit extremely low Txnip mRNA. The repressed Txnip
evoked significantly reduced Chrebp mRNA after culture at
5mMglucose compared with wild-type (WT) INS-1 cells (Figures
3C and 3D). After 72 hr exposure to 20 mM glucose, the Chrebp
transcript is further decreased, while Txnip levels are upregu-
lated, reaching those of the 5-mM-cultured WT-INS-1 cells.
Such an attenuated induction of Txnip was already described
for the Ep300 KO cells (Bompada et al., 2016). INS-1
(Ep300/) cells are completely protected from the glucotoxic-
ity-induced increase in VDAC1 mRNA (Figure 3E). Conversely,
VDAC2 mRNA in INS-1 (Ep300/) cells is already elevated un-
der physiological glucose and, rather than decreasing, further
increases in the high glucose condition (Figure 3F). Based on the
foregoing results, low VDAC1 combined with high VDAC2
expression should preserve GSIS. Hence, INS-1 (Ep300/) cells
display similar GSIS after 5 mM glucose culture as the WT cells.
The Ep300-KO cells are substantially, but not completely, pro-
tected from glucotoxicity-mediated abrogation of GSIS (Fig-
ure 3G). The incomplete restoration is not due to changes in
cellular insulin content (Figure S3D). Epigenetic mechanisms
have been implemented in the development of b cell dysfunction
in T2D through environmental stress (Nilsson and Ling, 2017).
Our results support this link, as glucotoxicity-mediated VDAC1
overexpression requires the histone acetyltransferase Ep300
for the transcriptional activation of TXNIP.
VDAC1 Overexpression Leads to Its Mistargeting to the
b Cell Membrane
The impaired metabolism-secretion coupling prompted us to
examine the cellular localization of VDAC1 and VDAC2. Extra-
mitochondrial plasma membrane VDAC1 (De Pinto et al., 2010;
Stadtmuller et al., 1999; Thinnes, 2015) participates in volume
regulation, ATP and metabolite transport, and intrinsic mito-
chondrial apoptosis (Akanda et al., 2008; Okada et al., 2004;
Shoshan-Barmatz et al., 2010). Remarkably, confocal micro-
scopy reveals that VDAC1, but not VDAC2, surface expression
occurs in b cells from T2D donors (Figures 4A and 4B). In ND
and in the single donor of four with documented metformin ther-
apy we could examine (cf. Figure 1C), VDAC1 remains intracel-
lular (Figures 4A and 4B). VDAC1 surface expression correlates
positively with the islet donor HbA1c when ND and T2D islets
were pooled (Figure 4C). The surface localization may thus be
a consequence of the organ donors’ high plasma glucose con-
centrations. To further substantiate the surface localization of
VDAC1, we performed triple immunofluorescence staining in
pancreas sections of ND and T2D donors. VDAC1 is clearly over-
expressed at the T2D b cell surface, as shown by the co-locali-
zation with the plasma membrane-associated SNARE protein
SNAP-25 (Figures 4D and 4E). Similar to the observations in
pancreas sections, b cells in islets isolated from a single T2D
donor also show intense VDAC1 overexpression (Figure 4F).
Similar results were obtained in b cell of ND islets kept in culture
for 72 hr at 20 mM glucose relative to control conditions (Fig-
ure 4G) or INS-1 cells (Figures S4A and S4B). Thus, VDAC1 mis-
targeting to the plasmamembranemay cause the impaired GSIS
in glucotoxicity and T2D. It is of interest, in this context, thatmito-
chondrial VDAC1 protein is reduced in T2D b cells (Thivolet et al.,
2017). Of note, in AD, VDAC1 is also upregulated in neurons of
affected brain areas early in the condition, and associated with
translocation of the protein to the neurolemma (Fernandez-
Echevarria et al., 2014).
VDAC1SurfaceExpressionCauses VDAC1Upregulation
Subsequently, we studied the functional consequences of
aberrant VDAC1 subcellular localization. The mouse Vdac1
gene is alternatively transcribed, yielding an exon1 splice
variant encoding a plasma membrane-targeted protein
(plVDAC1) (Buettner et al., 2000). Such splicing is not occurring
in the human and rat VDAC1 genes (see Figures S1E and S1F;
see also Raghavan et al., 2012). We postulate that VDAC1 over-
expression leads to its targeting to extra-mitochondrial loca-tions. Plasma membrane resident VDAC1 has been docu-
mented in various mouse and human tissues with the
mitochondrial surface residues facing the extracellular space
(Akanda et al., 2008; Buettner et al., 2000; De Pinto et al.,
2010; Okada et al., 2004; Stadtmuller et al., 1999; Thinnes,
2015). In neurons, plVDAC1 activation initiated apoptosis, pre-
vented by antibodies directed against the extracellular N termi-
nus of VDAC1 (Akanda et al., 2008; Smilansky et al., 2015).
Therefore, we investigated whether VDAC1 antibody, VBIT-4
and AKOS022075291 (AKOS), two specific small-molecule
VDAC inhibitors (Ben-Hail et al., 2016), affect glucotoxicity-
evoked VDAC1 induction in INS-1 cells, like metformin in hu-
man islets (Figure 1F). Indeed, not only metformin but also all
three VDAC inhibitors prevent glucotoxicity-mediated overex-
pression of VDAC1 mRNA (Figures S4C and S4D). Moreover,
inclusion of VBIT-4 in the 20 mM glucose culture of ND islets
also decreases VDAC1 protein expression (Figure 4G). Thus,
VDAC1 overexpression is prevented by metformin and inhibi-
tors of VDAC1, suggesting that, as in neurons (Akanda et al.,
2008), plVDAC1 conductance is harmful and notably affecting
gene transcription in b cells. Of note, in the limited number of
T2D donors with documented metformin therapy, there was
no VDAC1 overexpression (cf. Figure 1C). The putative protec-
tive action of metformin was substantiated by our in vitro exper-
iments. Metformin at a low therapeutic concentration prevented
the high glucose-evoked changes in VDAC1 and VDAC2
expression in islets and INS-1 cells. Metformin inhibits gluco-
toxicity-evoked TXNIP induction in both insulin-secreting
(Shaked et al., 2011) and endothelial cells (Li et al., 2015), which
are important targets for insulin action. In diabetic mice, VDAC1
upregulation causes apoptosis in heart coronary endothelial
cells (Sasaki et al., 2012), whose malfunction is conducive in
T2D cardiovascular complications. Moreover, VDAC1 is upre-
gulated in a model of diabetic cardiomyopathy and in cardio-
myocytes cultured under glucotoxic conditions (Li et al.,
2016). The action of metformin was reported to be due to stim-
ulation of AMPK (Foretz et al., 2014), which prevents ChREBP
nuclear translocation and TXNIP transcriptional activation
(Li et al., 2015; Shaked et al., 2011; Shalev, 2014).
VDAC1 Mistargeting to the Cell Membrane Causes
Cellular ATP Depletion
To further study the consequence of VDAC1 overexpression, we
monitored ATP levels during 1-hr experiments in plVdac1-ex-
pressing INS-1 cells. Overexpression of WT Vdac1 (mt Vdac1)
leads to a 3-fold increase in ATP release from the cells (Fig-
ure 5A), suggesting mistargeting of the ATP-conducting Vdac1
to the plasma membrane. This is substantiated by plVdac1
expression, which causes a 10-fold ATP loss (Figure 5A). The
robust GSIS in cells transfected with control plasmid is markedly
reduced in mtVdac1-transfected cells and completely abolished
in plVdac1-expressing cells (Figure 5B). Moreover, glucose
(20 mM) aggravates the marginal cell death in mtVdac1 cells,
while plVdac1 alone is more harmful (Figures S5A and S5B). In
plVdac1 cells, the loss of ATP is rapidly (1 hr) inhibited not only
by VDAC1 antibody, the VDAC inhibitors AKOS and VBIT-4,
but also by metformin (Figure 5C). VDAC1 overexpression thus
leads to ATP loss as a consequence of its translocation to the
plasma membrane.Cell Metabolism 29, 64–77, January 8, 2019 69
Figure 4. VDAC1 Localization in b Cells from ND and T2D Islet Donors
(A) Representative immunofluorescence images of VDAC1 and VDAC2 in human islet b cells from non-diabetic (ND) and T2D donors, one of whom had received
metformin therapy. Note VDAC1 expressed prominently on the b cell surface in T2D islets.
(B) b cell surface expression of VDAC1 given as ratio of surface/cytosolic VDAC1 immunofluorescence intensity in b cells of ND or T2D (12–15 cells/donor were
acquired for the analysis, 8 donors each in the ND and T2D group) and the one with metformin therapy (12 cells).
(C) Correlation between VDAC1 b cell surface expression and HbA1c values in 15 islet donors (ND and T2D).
(D) Confocal image of VDAC1 co-localization with SNAP-25 by double immunostaining in insulin-positive cells in pancreatic sections from ND and T2D donors
(3 donors with 27 islets in each group). Scale bar indicates 5 mm. Arrows show co-localization of VDAC1 and SNAP-25 also magnified in the squares. Mean
SNAP-25 intensity/islet was 10.2 ± 2.4 for ND and 10.5 ± 3.9 for T2D, respectively.
(E) Calculation of coefficients (VDAC1/SNAP-25) was performed using a confocal image analyzer (ZEN2012).
(F) Representative immunofluorescence images of VDAC1 expression in isolated islets from two ND and one T2D donor. Mean ± SEM of 12–20 islets from each
condition were analyzed.
(G) Representative immunofluorescence images of VDAC1 expression and its co-staining with insulin-positive cells in islets from two ND donors cultured at 5 or
20 mM glucose ± VBIT-4 (20 mM) for 72 hr. Scale bar indicates 10 mm.Metformin Inhibits VDAC1 Solute Conductance
Altered membrane permeability is further substantiated by
patch-clamp experiments (Buda et al., 2013). Indeed, plVdac1-70 Cell Metabolism 29, 64–77, January 8, 2019expressing INS-1 cells show 30% higher membrane conduc-
tance than mtVdac1-transfected cells (Figure S5C). The
increased conductance caused by plVdac1 relative to control
Figure 5. VDAC1 Cell Surface Expression Alters INS-1 Cell ATP Handling, Insulin Secretion, and Membrane Conductance
(A) ATP release after 1 hr incubation at 1 or 16.7 mM glucose from INS-1 cells transfected with either mitochondrial Vdac1 (mtVdac1) or plasma membrane-
targeted Vdac1 (plVdac1) and control (empty plasmid). Mean ± SEM (n = 4).
(B) GSIS measured in the same experiments as in (A).
(C) Effect of VDAC1 antibody (VDAC1-ab, 10 nM), metformin, or the VDAC1 inhibitors AKOS022075291 and VBIT-4 (20 mM each) on ATP release after 1 hr
exposure at 1 mM glucose of INS-1 cells transfected with control plasmid or plVdac1. Mean ± SEM from at least three independent experiments.
(D) Membrane conductance (whole-cell patch clamp) in control and plVdac1-transfected INS-1 cells in the presence or absence of metformin (20 mM) within 1 hr.
Mean ± SEM of 15 cells in each group are shown.
(E) Metformin (30 mM) reduces conductance of VDAC1 reconstituted in planar lipid bilayers. Average steady-state conductance measured at the indicated
voltage, before (d) and 10–30 min after metformin addition (B). Mean ± SEM of three independent measurements. A representative trace at 10 mV is shown at
the top.
(F) Same as in (E) using VBIT-4 (20 mM).
(G) Interaction of VBIT-4 (d) or metformin (B) with soluble VDAC1 (162 nM), using microscale thermophoresis. Results are presented as percent of the bound
fraction calculated as given in method.INS-1 cells is abolished by the acute addition of either VDAC1
antibody (Figure S5D) or metformin (Figure 5D). Superfusion
with metformin does not affect membrane currents in control
INS-1 cells while abrogating the elevated conductance in
plVdac1-transfected cells (Figure 5D).
As mtVDAC1 and pl-VDAC1 display identical amino acid se-
quences (Shoshan-Barmatz et al., 2010; Stadtmuller et al.,
1999), we next performed channel conductance recordings
with purified mitochondrial VDAC1 protein reconstituted into
planar lipid bilayers (Ben-Hail et al., 2016). Metformin (30 mM)
decreases channel conductance to a low conducting state
imposed (Figures 5E, S5E, and S5F) like the specific VDAC inhib-
itor VBIT-4 (Figures 5F, S5G, and S5H). Nonetheless, metformin
binding to VDAC1 might be voltage dependent, as 20 min prein-
cubation with 100 mM metformin causes stronger current inhibi-
tion (at ±60 mV) in the isolated channel preparation (results notshown). These results demonstrate that metformin at low, thera-
peutic concentrations, directly inhibits VDAC1 conductance. To
achieve quantitative analysis of the interaction of metformin with
VDAC1 and extract a binding affinity coefficient (Kd) for the inter-
action we usedmicroscale thermophoresis (MST). MST is based
on changes in the diffusion of the complex protein-ligand. In
contrast to VBIT-4, there is no apparent binding to VDAC1 of
metformin (concentrations from 0.625 to 200 mM) (Figure 5G).
Metformin inhibits the bilayer reconstituted-VDAC1 conduc-
tance but shows no apparent interaction with soluble protein.
This may be due to failure of inducing changes in protein confor-
mation detectable by thermophoresis. Furthermore, the acute
effect of metformin on VDAC1 solute permeation in intact cells
is not mediated via activation of AMP kinase (Foretz et al.,
2014) or through an antioxidant effect (Figure S5I). VDAC1 is a
target in cancer therapy (Shoshan-Barmatz et al., 2017) andCell Metabolism 29, 64–77, January 8, 2019 71
the chemopreventive action of metformin (Safe et al., 2018) may
in part be exerted through the here reported VDAC1 inhibition.
VDAC1 Surface Expression Involves Its Two Cysteine
Residues
Cell surface mistargeting of VDAC1 in T2D may involve post-
translational modification of its two cysteine residues (cys127/
232) (Aram et al., 2010; Piroli et al., 2016), although they are
not important for VDAC1-induced apoptosis (Aram et al.,
2010). Cysteine-depleted Vdac1 ismuchmore efficiently overex-
pressed in INS-1 cells than mtVdac1, while the reciprocal sup-
pression of Vdac2 observed after mtVDAC1 overexpression
(cf. Figures S2A and S2B) is absent (Figures 6A and 6B). Despite
the much higher expression, cysteine-depleted Vdac1 shows
50% less plasma membrane near localization than mtVdac1,
as revealed by total internal reflection fluorescence microscopy
(see Buda et al., 2013) (Figures 6C and 6D). Moreover, in contrast
to mtVDAC1, the cellular ATP/ADP ratio and its increase by
glucose stimulation are largely preserved (Figures 6E, 6F,
and S6), as is cellular ATP content (Figure 6G). Furthermore,
cysteine-depleted Vdac1-expressing cells do not display
increased ATP release, which is very pronounced in mtVdac1
cells (Figure 6H). The preserved cellular ATP content and ATP
generation by glucose explain the near normal GSIS in the cells
transfected with the mutant VDAC1 (Figure 6I). These results are
compatible with VDAC1 targeting to the b cell plasmamembrane
by post-translational cysteine modification, leading to ATP loss
from the cells and impaired GSIS.
VDAC1 Surface Expression Causes Impaired GSIS in
Islets from Diabetic Mice
Next, we investigated islet cells from diabetic db/db mice. Like
islets from T2D donors, b cells from hyperglycemic db/db, but
not from normoglycemic C57/bl, mice show surface expression
of VDAC1 (Figures S7A and S7B). This is associated with
increased Vdac1 mRNA (Figure S7C). ATP levels in islets from
hyperglycemic db/db mice are not raised by 16.7 mM glucose
and there is increased ATP release (Figures 7A and 7B). As ex-
pected from the VDAC1 surface localization, acute addition
(1 hr) of VDAC1 antibody or metformin reduces ATP release
and increases its cellular levels (Figures 7A and 7B). Conse-
quently, ATP generation and GSIS are markedly enhanced
when VDAC1 is inhibited during the high glucose stimulation
(Figures 7A and 7C). Neither ATP content nor the stimulated
GSIS is affected by VDAC1 inhibitors, including VBIT-4, in islets
from normoglycemic C57/bl mice (Figures S7D and S7E), con-
firming that VDAC1 mistargeting is restricted to diabetic b cells.
Inhibition of VDAC1 Restores Insulin Secretion in T2D
Donor Islets
Subsequently, we investigated whether inhibiting cell membrane
VDAC1 conductivity also could ameliorate b cell function in hu-
man islets. Inhibition of VDAC1 using metformin, VDAC1 inhibi-
tors, or antibodies does not alter ATP content and cellular reduc-
tive capacity after culture at 5 mM glucose, but markedly
improves metabolism during glucotoxic conditions or in T2D is-
lets (Figures S7F and S7G). Inclusion of VDAC1 antibody or met-
formin in the culture medium, while not affecting secretion after
culture at 5 mM glucose, prevents the attenuation of GSIS72 Cell Metabolism 29, 64–77, January 8, 2019observed in the islets cultured at 20 mM glucose (Figure 7D).
Similar results were previously reportedwithmetformin in human
islets under glucotoxic conditions (Masini et al., 2014) and the
drug improved the function of T2D islets (Marchetti et al.,
2004). To probe for membrane effects of VDAC1 antibody,
metformin, or VBIT-4, we pooled results of islets from five T2D
donors and one with IGT. After only 1 hr exposure to the com-
pounds, VDAC1 inhibition increases islet ATP content both at 1
and 16.7 mM glucose. Notably, the ATP-increasing effect of
glucose is 5-fold enhanced by VDAC1 inhibition (Figure 7E).
The T2D islets display severe blunting of GSIS. Remarkably,
GSIS is increased nearly 4-fold in parallel with the improved
ATP generation by each of the four VDAC1 inhibitors (Figure 7F;
cf. 2I and 7D for GSIS in ND islets). Of note, acute addition of
VBIT-4 concentrations up to 100 mM does not affect GSIS in
ND islets (Figure S7H). Thus, GSIS is markedly improved in
T2D islets by the acute inhibition of plVDAC1, suggesting that
VDAC1 mistargeting rather than the decreased VDAC2 gene
expression (cf. Figures 1A–1E) underlies the impaired b cell func-
tion. It cannot be excluded that the decreased VDAC2 expres-
sion or reduced b cell mass (Marselli et al., 2014; Meier and
Bonadonna, 2013) in the T2D islets underlies the incomplete
restoration of GSIS.
Inhibition of VDAC1 Prevents Hyperglycemia in
db/db Mice
The encouraging results in T2D islets prompted us to study the
effects of the VDAC1 inhibitor VBIT-4 in vivo. To this end, we sub-
jected diabetes-prone young db/dbmice to daily intraperitoneal
injections of VBIT-4 for 5 weeks, starting at age 42 days. This
treatment is not affecting blood glucose in control C57/bl mice
but prevents the development of the severe hyperglycemia,
seen in vehicle-injected db/db mice. Upon VBIT-4 cessation,
blood glucose concentrations increase gradually over several
weeks, reaching those of vehicle-treated animals (Figure 7G).
There is no effect on bodyweight (Figure S7I). The drugmarkedly
improves glucose tolerance and GSIS in vivo (Figures 7H–7J and
S7J). Insulin sensitivity was also improved in the treated db/db
mice as calculated by the homeostasis model assessment of in-
sulin resistance (HOMA-IR) (Bowe et al., 2014) (Figure S7K),
which may reflect involvement of altered VDAC1 expression in
insulin target tissues (Li et al., 2016; Sasaki et al., 2012). GSIS
was also normalized in islets isolated from VBIT-4-treated
db/db mice (Figure S7L). The early administration of VBIT-4
also prevents increases in water consumption and polyuria in
the db/db mice, but only marginally lowers blood glucose in
14-week-old animals with manifest hyperglycemia (data not
shown). It is noteworthy, that VBIT-4 appears to bemore efficient
than metformin administered before the outbreak of diabetes in
the same animal model (Cao et al., 2014). A possible explanation
is that metformin inhibits VDAC1 conductance less efficiently
than VBIT-4. Nonetheless, both metformin and VBIT-4 also
counteracted VDAC1 overexpression, preventing mistargeting
to the b cell surface under glucotoxic conditions (see scheme
in Figure S7M). Collectively, early initiation of therapy with a
VDAC1 inhibitor blocks the development of diabetes in this
T2D mouse model. Through the prevention of VDAC1 gene
expression, VBIT-4 may have disease-modifying actions. We
base this on the remarkable delay (at least 3 weeks) in the
Figure 6. Overexpression of desCys(127/232)VDAC1 (Des-CysVDAC1) Is Less Harmful for INS-1 Cell Function than mtVDAC1
(A and B) Vdac1 mRNA expression (A) and Vdac2 mRNA expression (B) in cells transfected with mtVdac1 or Des-CysVdac1. Results are mean ± SEM of four
independent experiments with 1–4 replicates in each.
(C) Representative image of plasma membrane-near localization of mtVdac1 or Des-CysVdac1 in INS-1 cells assessed by total internal reflection fluorescence
microscopy. Scale bar indicates 5 mm.
(D) Surface density of mtVdac1 and Des-CysVdac1 in INS-1 cells; Mean ± SEM of 30 cells each from three independent experiments.
(E) Cytosolic ATP/ADP ratio measured in single INS-1 cells (Ex/Em 488/520, 37C) by confocal microscopy after co-transfection with PercevalHR and either
mtVdac1 or Des-CysVdac1.
(F) Glucose-induced increases in cytosolic ATP/ADP ratio are largely preserved in des-Vdac1 and abolished in mtVdac1 overexpressing INS-1 cells. AUC for
glucose stimulation of five to ten analyzed cells from six different experiments, for AUC of the values after oligomycin addition (see Figure S6).
(G–I) ATP content (G), ATP release (H), and insulin release (I) from INS-1 cells transfected with empty plasmid (Ctr), Des-CysVDAC1, or mtVDAC1 plasmids and
incubated at 1 mM (1G) or 16.7 mM glucose (16.7G) for 1 hr (n = 5).
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Figure 7. Inhibition of Cell Surface Mistargeted VDAC1 Restores GSIS in Prediabetic db/db Mice and in Human T2D Islets
(A–C) One-hour exposure to VDAC1 antibody (10 nM) or metformin (20 mM) restores impaired glucose-stimulated ATP generation in islets of diabetic db/dbmice
in parallel with suppression of ATP release (B) and augments GSIS (C). Mean ± SEM (n = 4).
(legend continued on next page)
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establishment of severe hyperglycemia after discontinuation of
the compound.
Conclusion
We demonstrate that the harmful effects of glucose cause
VDAC1 induction in T2D. This novel diabetes executer protein
impairs b cell metabolism-secretion coupling through its mistar-
geting to the b cell membrane with consequent ATP depletion
(Figure S7M). Our results suggest VDAC1 as a novel target in dia-
betes therapywith the potential to prevent progression of predia-
betes to overt T2D.We also report thatmetformin inhibits VDAC1
function, a novel mechanism of action for the antidiabetic drug.
The b cell protective action of metformin with ameliorated insulin
secretion rather than improved insulin effectiveness was recently
reported in T2D subjects (Retnakaran et al., 2018). It is likely that
this beneficial effect targets VDAC1 gene expression and func-
tion in the b cells.
Limitations of Study
The main limitations of the current study are the limited experi-
ments in diabetic animal models. In particular, in-depth analysis
of the relative importance of VDAC1 inhibition for the ameliora-
tion of insulin secretion from the b cells relative to action on insu-
lin target tissues, such as liver, muscle, and fat, needs to be per-
formed. It would also be important to crossbreed diabetic mice
with Vdac1-KO mice. This is, however, difficult due to the
reduced fertility of Vdac1-KO mice (Raghavan et al., 2012). The
reciprocal regulation of gene expression between VDAC1 and
VDAC2, which we have reported, requires further investigation
both in vitro and in vivo. However, such in vivo studies would
require b cell-targeted Vdac1 and Vdac2 deletion, as global
Vdac2-KO mice are embryonic lethal (Raghavan et al., 2012).
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell line
INS-1 832/13 cells derived from male rat insulinoma were kindly donated by Dr. C. B. Newgaard, Duke University, (USA).
Human Islet Preparations
Human pancreatic islets were obtained through collaboration between Human Tissue Laboratory within Lund University Diabetes
Centre (LUDC) and the Nordic Network for Clinical Islet Transplantation (Prof. Olle Korsgren, Uppsala University, Sweden). Donors
were grouped according to HbA1c i.e. less than 6% (ND), between 6% and 6.5% (IGT), higher than 6.5% or history of diabetes (T2D)
(See Table S1). The human islets (70-90 % purity) had been cultured in CMRL 1066 (ICN Biomedicals, Costa Mesa, CA) supple-
mented with 10 mM HEPES, 2 mM L-glutamine, 50 mg/ml gentamicin, 0.25 mg/ml fungizone (Gibco, BRL, Gaithersburg, MD),
20 mg/ml ciprofloxacin (Bayer Healthcare, Leverkusen, Germany) and 10 mM nicotinamide at 37C (5% CO2) for 1 to 5 days prior
to the arrival in the laboratory. The islets were then hand-picked under stereomicroscope prior to use. All procedures using human
islets were approved by the ethical committees at Uppsala and Lund Universities, Sweden.
Mouse Islet Preparations
5 weeks old Female db/db (on the B6/KS genetic background) mice and control (C57/bl) weighing 18-25 g, were from Janvier Lab-
oratory, France). The experimental procedures were approved by the Ethics Committee for Animal Research at Lund University. The
animals were given a standard pellet diet (B&K) and tap water ad libitum. Isolation of pancreatic islets was performed by retrograde




INS-1 832/13 cells were cultured in RPMI-1640 containing 11.1 mM D-glucose and supplemented with 10% fetal bovine serum,
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2mMglutamine, 1mM sodium pyruvate, and 50 mM b-mercaptoethanol (Sigma), at 37ΊC in a humidified atmosphere containing 95%
air and 5% CO2. For VDAC1 over-expression by VDAC1 plasmid (1 mg/ml) and VDAC2 down-regulation by and siRNA, INS1 cells
were cultured to 60% confluence. To study the long-term effects (24-72h) of high glucose (20 mM) (glucotoxicity) compared to basal
glucose (5 mM), INS-1 cells were cultured with RPMI 1640 complete media (Ahmed et al., 2010) in the presence or absence of indi-
cated agents and thereafter VDAC1 expression levels, cell viability and function were measured.
Plasmid and Transient Transfections
INS1 cells were seeded in six-well plates at a density of 5 x 105 cells in culture medium without antibiotics and transfected with
full-length cDNA encoding prevalidated VDAC1 construct (1 mg/ml plasmid) encoding VDAC1 or control plasmid (non-coding) using
Effectene Transfection Reagent (Qiagen) according to the manufacturer’s instructions. Tween four post transfection, medium was
replaced with fresh medium containing antibiotics. If not indicated otherwise, at 72h post-transfection, the cells were harvested
and analyzed by immunoblotting and qPCR for the relative level of various proteins and mRNA.
Histone Acetyltransferase p300 (Ep300) Knock- out Cells
Histone acetyltransferase p300 (Ep300) was knocked out in the rat pancreatic b-cell line (INS1 832/13) by CRISPR/Cas9 as recently
described (Bompada et al., 2016).
Insulin Secretion in Cultured INS-1 Cells
Cells with VDAC1 over-expressed or VDAC2 down-regulated were used to measure the insulin secretion. To this end, INS-1 cells
were kept in HEPES balanced salt solution (HBSS; 114 mM NaCl; 4.7 mM KCl; 1.2 mM KH2PO4; 1.16 mM MgSO4; 20 mM
HEPES; 2.5 mM CaCl2; 25.5 mM NaHCO3; 0.2% BSA, pH 7.2) supplemented with 2.8 mM glucose for 2 h at 37C. Thereafter
the cells were incubated for 1 h in the fresh medium with the denoted glucose concentrations and test agents. After incubation
an aliquot of medium was removed for analysis of secreted insulin and cellular insulin content was measured as for islets
(see below).
Conductance Measurement by Patch Clamp Recording
For electrophysiological experiments, INS-1 cells were transiently co-transfected with plVDAC1 and eGFP. Both intensely and less
Fluorescent cells were selected for patch clamping. Whole-cell currents were evoked and recorded by EPC10 amplifier and Pulse
software (HEKA, Lambrecht/Pfalz, Germany) as previously described (Buda et al., 2013) with the temperature maintained at 32C.
The cells were continuously perfused with extracellular solution containing 118 mM NaCl, 20 mM tetraethylammonium chloride,
5.6 mM KCl, 2.6 mM CaCl2, 1.2 mM MgCl2, 5 mM HEPES and 5 mM glucose (pH 7.4 with NaOH) in the presence of 100 uM tolbu-
tamide (T0891, Sigma-Aldrich). The intracellular solution consisted of 125mMCs-glutamate, 10mMCsCl, 10mMNaCl, 1mMMgCl2,
5 mM HEPES, 3mMMg-ATP, 0.1 mM cAMP and 0.05 mM EGTA (pH 7.2 with CsOH). 20 uM metformin was used for perfusion, and
approximately 8 mM metformin or 130 nM VDAC1 antibody (both diluted approximately 100 fold) for acute addition as indicated in
figure legends or text. Conductance was measured by applying 200-ms voltage ramps from -90mV to -50mV. In the experiments
studying the effects of acute addition of VDAC1 ab or metformin (Figures S5C and S5D), conductance was measured continuously
in the same single cell before, during and after the acute addition of the respective compounds (anti-VDAC1 antibodies ormetformin).
Data presented are from 15 s after the addition when steady-state was reached.
For experiments in Figure 5D, the cell dish in the experimental chamber was continuously exposed to 20 mMmetformin. Conduc-
tance measurements were performed after at least 5 minutes exposure, and the cell dish was replaced no later than after 1 hour of
perfusion. No wash-out experiments were performed in this experiment.
VDAC Current Measurement on the Reconstituted VDAC1 in Planar Lipid Bilayer (PLB)
VDAC1 was purified from rat liver mitochondria as described previously (Ben-Hail et al., 2016). To measure single and multiple
channel current, a planar lipid bilayer (PLB) was prepared from soybean asolectin dissolved in n-decane (30 mg/ml). Purified
VDAC1 (10–100 ng) was added to the chamber defined as the cis side containing 0.5 M NaCl. After one or a few channels were in-
serted into the PLB, excess protein was removed by perfusing the cis chamber with10 volumes of solution to prevent further chan-
nel incorporation. Following several recordings of channel activity at different voltages, metformin or VBIT-4 was added to the cis
chamber, and currents through the channel were again recorded. Currents were recorded by voltage-clamping using a Bilayer Clamp
BC-535B amplifier (Warner Instruments, Hamden, CT). Currents were measured with respect to the trans side of the membrane
(ground). The currents were low pass-filtered at 1 kHz and digitized online using a Digidata 1440-interface board and Clampex soft-
ware (Axon Instruments, Union City, CA). Analysis was done using pClamp 10.2 software (Axon Instruments, Union City, CA), or excel
(Microsoft).
VDAC1 Binding Study
The binding study on the purified VDAC1 channel protein performed using a Nano-Temper Monolith NT.115 apparatus as described
previously (Ben-Hail et al., 2016). Briefly, purified VDAC1 was fluorescently labeled using NanoTemper Protein labeling kit BLUE
(L001, NanoTemper Technologies). A constant concentration of the protein was incubated with different concentrations of the tested
inhibitor in PBS. Afterward, 3–5 ml of the samples were loaded into a glass capillary (Monolith NT Capillaries), and thermophoresise3 Cell Metabolism 29, 64–77.e1–e6, January 8, 2019
analysis was performed (LED 20%, IR laser 20%). The results are presented as%of the bound fraction calculated as follows: fraction
bound100x(F - F min)/(F max-F min).
Intraperitoneal Glucose Tolerance Tests (IPGTT)
IPGTTs were performed in db/db and c57/bl mice after treatment with VDAC1 blocker (daily intraperitoneal injection with VBIT-4,
25 mg/kg body weight) for 5 weeks. Prior to IPGTT test, the mice were fasted for 4 h. Glucose was dissolved in 0.9% NaCl and
2.0 g glucose/kg body weight was injected intraperitoneally (total volume load was 0.3 ml). Serial blood sampling thereafter from
vena saphena was performed at 0, 5, 15, 30 and 90 min as previously described elsewhere (Bowe et al., 2014). Blood glucose
was analyzed using glucose oxidase method and plasma insulin was analyzed by ELISA. The Cumulative (area under the curve)
changes in plasma glucose or insulin were calculated by subtracting the recorded values from basal (time 0). The homeostasis model
assessment of insulin resistance (HOMA-IR) (insulin (mU/l)*glucose (mmol/l)/22.5) was used to calculate insulin sensitivity during the
IPGTT as described (Bowe et al., 2014).
Glucose-stimulated Insulin Secretion (GSIS) in Human and Mouse Islets
Human pancreatic islets were collected under a stereomicroscope at room temperature and cultured at 5 or 20 mM glucose in the
absence or presence of test agents for 72 h. Thereafter the islets were washed and preincubated for 30 min at 37C in Krebs Ringer
bicarbonate buffer (KRB), pH 7.4, supplemented with HEPES (10 mM), 0.1% bovine serum albumin, and 1 mM glucose. Each incu-
bation vial contained 12 islets in 1.0 ml KRB buffer solution and treated with 95%O2 and 5%CO2 to obtain constant pH and oxygen-
ation. After preincubation, the buffer was changed to a medium containing either 1 mM or 16.7 mM glucose. The islets were then
incubated for 1 h at 37C in a metabolic shaker (30 cycles per min). Immediately after incubation an aliquot of the medium was
removed for analysis of insulin, and the islets were incubated in acid-ethanol for insulin content determination by radioimmunoassay
(Wiederkehr et al., 2011).
Quantitative Polymerase Chain Reaction (qPCR)
Total RNA from handpicked mouse islets, human donor islets (Diabetic and non-diabetic) or INS1 cells were extracted using
RNAeasy (Qiagen, Hilden, Germany). RNA (0.5 mg) was used for cDNA synthesis with SuperScript (Invitrogen, Carlsbad, CA,
USA). Concentration and purity of total RNA was measured with a NanoDrop ND-1000 spectrophotometer (A260/A280>1.9 and
A260/A230>1.4) (NanoDrop Technologies, Wilmington, DE) and RNA Quality Indicator (RQI) higher than 8.0 (Experion Automated
Electrophoresis, Bio-Rad, USA) was considered to be high-quality total RNA preparations. A 10 ml of reaction mixture with 20 ng
cDNA, 5 ml TaqMan mastermix (Applied Biosystems, Foster City, CA, USA), and 100 nM TagMan gene expression assay were run
in a 7900HT Fast Real-Time System (Applied Biosystems). The qPCR was carried out as follows: 50C for 2 minutes, 95C for 10 mi-
nutes, 40 cycles of 95C for 15 seconds, and 60C for 1minute. The amount of mRNAwas calculated relative to the amount of house-
keeping genes (GAPDH, PPIA or HPRT) mRNA in the same sample by the formula X0/R0 = 2CtR-CtX, where X0 is the original amount
of mRNA for the gene of interest, R0 is the original amount of HPRT mRNA, CtR the Ct value for HPRT, and CtX the Ct value for the
gene of interest. qPCR results were normalized to housekeeping genes. Primer sequences used in the qPCR assays are provided in
Table S2.
To measure the expression level of VDAC1 and VDAC2 under glucotoxic (20 mM glucose) compared to normal condition (5 mM
glucose), human islets (300 islets/30 mm Dish) were cultured in RPMI 1640 medium containing either 5 or 20 mM glucose with or
without indicated test agents in a humidified incubator (37C, 5% CO2) for 24 to 72 h. VDAC1 and VDAC2 mRNA and protein levels
were investigated by both qPCR (relative to GAPDH, HPRT or PPIA) and Western blotting (relative to the expression of and b-actin),
respectively.
Immunoblotting
Human islet or INS1 832/13 cells were suspended in 100 ml of SDS-buffer (50 mMTris-HCl, 1mMEDTA) supplemented with complete
protease inhibitor cocktail (Roche, Basel Switzerland), frozen and sonicated on ice on the day of analysis. The protein content of the
homogenates was determined by commercially available kit according to the manufacturer’s recommendation (Thermo Scientific,
USA). Homogenate samples of islets and INS1 cells representing 30 mg of total protein were subjected to 7.5% SDS-polyacrylamide
gels (Bio-Rad, Hercules, CA, USA). After electrophoresis, proteins were transferred into nitrocellulose membranes (Bio-Rad, Hercu-
les, CA, USA). Themembranes were blocked in LS-buffer (10mMTris, pH 7.4, 100mMNaCl, 0.1% Tween-20) containing 5%non-fat
dry milk powder for 40 min at 37C. Subsequently the membranes were incubated over night with rabbit-polyclonal anti-VDAC1 and
goat-polyclonal anti-VDAC2 antibodies (1:500) at room temperature. After washing (three times) in LS-buffer the membranes were
incubated with horseradish peroxidase-conjugated anti-goat or anti-rabbit antibodies (1:1000). Immunoreactivity was detected us-
ing an enhanced chemiluminescence reaction (Pierce, Rockford, IL, USA). The band-intensity was related to b-actin.
Immunostaining and Confocal Imaging
Isolated human or mouse islets as well as INS-1 cells were seeded on glass-bottom dishes cultured overnight. Cells were then
washed twice and fixed with 3% paraformaldehyde for 10 min, followed by permeabilization with 0.1% Triton-X 100 for 15 min.
The blocking solution contained 5% normal donkey serum in PBS and was used for 15 min. Primary antibodies against
mouse VDAC1 (Abcam), goat VDAC2 (Abcam) and Guinea pig insulin (Eurodiagnostica) were diluted in blocking buffer and incubatedCell Metabolism 29, 64–77.e1–e6, January 8, 2019 e4
overnight at 4C. Immunoreactivity was quantified using fluorescently labeled secondary antibodies (1:200) and visualized by
confocal microscopy (Carl Zeiss, Germany). The ratio is calculated by mean intensity of plasma membrane to mean intensity in








i : Where i1, i2 and i3 represent the intensities of whole cell, cytosol and nucleus,
a1, a2 and a3 represent the area of whole cell, cytosol and nucleus respectively (Buda et al., 2013).
Immunohistochemistry was performed following standard protocol. Briefly, the human pancreases were paraffin embedded, cut
into 10 um thick sections and rehydrated for staining with primary antibodies of guinea pig anti-insulin (Eurodiagnostica), rabbit
monoclonal anti-VDAC1 (Abcam) and mouse monoclonal anti-SNAP25 (SYSY) were used to detect insulin, VDAC1 and SNAP-25
expression, respectively. The nuclei were stained by Hoechst 33258. The human pancreatic sections from ND and T2D donors
were kindly provided by the Nordic Network for Islet transplantation (Prof. Olle Korsgren, Uppsala, Sweden). The images were ac-
quired by confocal microscopy and the colocalization analysis of VDAC1 and SNAP25 in insulin-staining cells was performed with
software ZEN2012.
Single Cell ATP/ADP Ratio Measurement
For single cell ATP/ADP ratio measurements, INS-1 cells were co-transfected as above with either wtVDAC1 or des-Cys(127/232)
VDAC1 plasmid (Aram et al., 2010) together with PercevalHR (1 mg/ml) each. Single cell imaging was performed by confocal micro-
scopy as described (Tantama and Yellen, 2014) and applied to INS-1 cells. Expression levels were determined by qPCR.
TIRF Microscopy
INS-1 cells were seeded on glass-bottom dishes and transfected with wild-type VDAC1-EGFP and des-Cys(127/232)VDAC1-EGFP for
48 hours. The membrane expression of wild type and des-Cys(127/232)VDAC1 was measured by TIRF imaging, which detects the
VDAC1 signal about 150 nm close to the glass surface. The analysis of VDAC1 spots was performed by ImageJ Plugin and ZEN2012
software. The experimentswere repeated3 timeswith 30 cells in eachgroup ofwild typeanddes-Cys(127/232)VDAC1transfectedcells.
Small Interfering RNA (siRNA) for Protein Expression Silencing
For VDAC1 and VDAC2 small interfering RNA (siRNA) experiments, 20-25 nucleotide stealth prevalidated siRNA duplex designed for
rat Vdac1 and Vdac2 (Applied Biosystem) were used. INS1 cells were seeded in six-well plates at a density of5 x 105 cells in culture
media without antibiotics and transfected with DharmaFECT1 (Dharmacon; Lafayette, CO, USA) according to the manufacturer’s in-
structions. Cells were transfected for 24 h with the Vdac1 and Vdac2 siRNA at a final concentration of 50 nM or with control siRNA
(non-targeting siRNA) at the same concentration before changing to fresh media including antibiotics. At 72 h after transfection, cells
were lysed to extract total RNA or protein to measure the knockdown efficacy.
For silencing Chrebp and Txnip expression in INS1 832/13 cells, 20-25 nucleotide stealth prevalidated siRNA duplex designed for
rat Chrebp and Txnip (Applied Biosystem) were used, following the same protocol as for VDAC silencing. At 72h after transfection,
cells were lysed to extract total RNA or protein to measure Chrebp and Txnip knockdown efficiency as well as VDAC1 expression.
Silencing by shRNA Mediated (Lentivirus) in Human Islets
Specific silencing of endogenous human hVDAC1 or hVDAC2 was achieved using lentiviral based shRNA-silencing technique (Santa
Cruz, CA, USA). Isolated human islets were incubated at 2.8 mM glucose plus Polybree for 90 min. Thereafter the medium was
removed and the islets were washed before addition of culture medium with lentiviral particle containing VDAC1-shRNA or
VDAC2-shRNA (5 ml/ml) and the islets were cultured for 72 h at 5 or 20 mM glucose. For comparison, scramble (lentiviral particles
without targeting any specific region) served as control. After the culture period the medium was removed and the islets were
dispersed into single cells and subjected to cell viability assay using MTS reagent kit.
Measurement of Cellular Reductive Capacity (MTS), Apoptosis and Viability
The reductive capacity of cells was measured either on INS-1 cells or dispersed human islet cells when the INS-1 cells or islets were
subjected to 5 or 20 mMglucose for 72 h in the absence or presence of test agents or after down-regulation of VDAC1 and VDAC2 as
described elsewhere. Measurement of reductive capacity was performed using the MTS reagent kit according to the manufacturer’s
instructions (Promega) and (Janjic andWollheim, 1992). Apoptosis was measured with the Cell Death Kit (Roche Diagnostics), which
quantifies the appearance of cytosolic nucleosomes.
To measure the cell viability in living cells, we used EthD1 (Ethidium homodimer-1) and calcein to indicate death and live cell in
INS-1 cells, respectively according to manufacturer (Thermo Fisher, USA). The plasma membrane targeted VDAC1 (plVDAC1)
and mitochondrial VDAC1 (mtVDAC1) were overexpressed in INS-1 cells cultured with either 5 mM glucose (5G) or 20 mM glucose
(20G). The mean intensity of Ethidium and Calcein were calculated to indicate live and death cells, respectively.
Measurement of Oxygen Consumption Rate (OCR)
OCR was measured in INS-1 832/13 cells using the XF (extracellular flux) analyzer XF24 (Seahorse Bioscience), as previously
described in detail (Wiederkehr et al., 2011). An assay medium composed of 114 mMNaCl, 4.7 mM KCl, 1.2 mM KH2PO4,e5 Cell Metabolism 29, 64–77.e1–e6, January 8, 2019
1.16mMMgSO4, 20 HEPES, 2.5 CaCl2, 0.2%bovine serum albumin, pH 7.2, and supplementedwith 2.8mMglucosewas used in the
XF analysis. The cells were seeded in an XF24 24-well cell culture microplate at 2.53105 cells/well (0.32 cm2 growth area) in 500 ml of
growth medium and incubated overnight at 37C in a humidified atmosphere of 95% air and 5%CO2. Prior to assay, RPMI 1640 me-
dium was removed and replaced with 750 ml of assay medium. The cells were preincubated under these conditions for 2 h at 37C in
air. The experiments were designed to determine respiration in low (2.8 mM) glucose and for 60 min following the transition to high
(16.7 mM) glucose. The proportions of respiration driving ATP synthesis and proton leak were determined by the addition of oligo-
mycin (4 mg/ml). After a further 30 min, 4 mM of dinitrophenol was added to determine maximal respiratory capacity. After a further
10 min, 1 mM rotenone was added to block transfer of electrons from complex I to ubiquinone.
ATP Determination
ATP content and release from isolated mouse or human islets or from INS-1 cells after transfection with mitochondrial targeted
VDAC1 (mtVDAC1) or plasma membrane targeted VDAC1 (plVDAC1) plasmids was determined using a luminometric assay kit
according to manufacturer’s recommendation (Biovision). After incubation of islets (50/vial) or INS-1 cells for 60 min, an aliquot of
the media was removed for subsequent measurements of released ATP. Then the islets or INS-1 cells were washed 3 times and
the lysates were used for measurements of ATP and protein contents following the protocol provided by the vendor.
Mitochondrial and Cytosolic Ca2+ Imaging in Single Cells
INS-1 cells (63105 cells) were seeded on 24-well plates and subjected to the following treatments: Control with 5 mM glucose,
VDAC1 overexpressed (OE) and silencing VDAC2 (KD) by siRNA in 5 mM glucose culture, and 3 days treated with 20 mM glucose.
24 hours prior to Ca2+ imaging, the cells were transferred to glass-bottom dishes while diluted 1:6 (13105 cells). The cells were
loaded 1 h with Rhod-2 (0.75 uM) and Fluo-5F (0.5 uM) dissolved in the perfusion buffer (KRB). Time lapse ROi images were acquired
by confocal microscopy and the mean intensity of ROIs was analyzed by ZEN 2009 software. The data calculation was performed
with Excel and normalized ratio was calculated by Fi/F0 (Buda et al., 2013).
QUANTIFICATION AND STATISTICAL ANALYSIS
The results are expressed as means ± SEM for the indicated number of individual experiments (as given in figure legends) or
illustrated by an observation representative of a result obtained from different experiments (Western blots). The significance of
random differences were analyzed by Student’s t-test or where indicated the analysis of variance followed by Tukey-Kramers’ mul-
tiple comparisons test. P value <0.05 was considered significant. All data were assessed to ensure normal distribution and equal
variance between different groups.
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